for the LIFE Study Group IMPORTANCE Whether sustained physical activity prevents cardiovascular disease (CVD) events in older adults is uncertain.
T here are few randomized clinical trials testing the ability of physical activity to prevent cardiovascular disease (CVD) events. Many observational studies demonstrate that greater physical activity (PA) is associated with lower rates of incident and recurrent myocardial infarction (MI) across a spectrum of age. [1] [2] [3] In clinical trials, physical activity interventions have been shown to slow the progression of coronary artery disease 4, 5 and can prolong event-free survival in patients undergoing stent placement. 6, 7 Cardiac rehabilitation trials show reduction in cardiovascular events for patients with recent cardiovascular illness, although most trials include risk-factor modification in addition to exercise training, making it difficult to isolate the effect of physical activity. Guidelines 8,9 extend recommendations for 150 minutes of moderate activity per week for middle-aged adults to older adults based on studies to date. However, these trials have not included many frail older adults who are at highest risk for CVD and disability. Thus, many questions remain as to the optimal frequency, intensity, and modality of physical activity for older adults. To our knowledge, whether a physical activity intervention can prevent CVD events in older, functionally limited individuals is unknown. The Lifestyle Independence and Interventions for Elders (LIFE) Study compared PA with health education and showed that a structured PA program can prevent mobility disability in older adults with functional limitations. In the trial, incident major mobility disability occurred in 30.1% of the PA group and 35.5% of the health education group (hazard ratio [HR], 0.82; 95% CI, 0.69-0.98). 10 As a tertiary outcome, we compared cardiovascular event rates between the 2 study groups. The PA intervention was conducted over an average of 2.5 years and included moderate aerobic activity, mostly walking, of at least 150 minutes per week; thus, the study can be viewed as an evaluation of the benefits of guidelines for prevention of CVD events.
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Methods
The LIFE study was a multicenter, 
Randomization
Participants were randomized to a PA or to a successful aging (SA) program via a secure, internet-based data management system using a permuted block algorithm (with random block lengths), stratified by field center and sex. Both groups received an initial individual 45-minute face-to-face introductory session by a health educator who described the intervention, communicated expectations, and answered questions.
Interventions
The PA intervention involved walking (with a goal of 150 minutes/week), strength training, flexibility training, and balance training. 11 The intervention included attendance at 2 center-based visits per week and home-based activity 3 to 4 times per week for the duration of the study. A protocol was in place to restart the intervention for the participants who suspended the PA for medical reasons. The PA sessions were individualized and progressed toward a goal of 30 minutes of walking daily at moderate intensity, 10 minutes of primarily lower extremity strength training by means of ankle weights (2 sets of 10 repetitions), 10 minutes of balance training, and
Key Points
Question Is cardiovascular morbidity and mortality reduced in participants in a long-term physical activity program?
Findings In a randomized trial cardiovascular disease events occurred in 14.8% of the physical activity group and 13.8% of the successful aging group. This difference was not significant.
Meaning Among participants in the LIFE Study, an aerobically based, moderately intensive physical activity program was not associated with reduced cardiovascular events in spite of the intervention's previously documented ability to prevent mobility disability.
sure intensity of activity. Participants were asked to walk at an intensity of 13 ("somewhat hard"), and lower extremity strengthening exercises were performed at an intensity of 15 to 16. The SA group attended weekly workshops of health education during the first 26 weeks and then monthly sessions thereafter.
Cardiovascular Disease Assessment
At baseline, prevalent CVD was defined as self-report of MI, congestive heart failure, stroke, or MI pattern on ECG. At each 6-month contact, all participants (or a proxy informant if the participant was unavailable) were questioned about all hospitalizations since the last visit. Proxy reports accounted for less than 0.1% of the follow-up contacts. Hospital records were obtained to abstract information for study criteria for the primary and secondary outcomes, masked to group assignment. Cardiovascular disease events were a predefined tertiary outcome and consisted of a composite of MI, hospitalized angina, hospitalized congestive heart failure, revascularization with bypass surgery or percutaneous angioplasty, ruptured abdominal aortic aneurysm, hospitalization for carotid artery disease, hospitalization for peripheral artery disease or outpatient revascularization for peripheral artery disease, any stroke, transient ischemic attack requiring hospitalization, and death from CVD. Records and abstraction forms were sent to the administrative coordinating center for central review by 2 physician investigators who were also masked to group assignment, with adjudication as definite or probable by 2 reviewers. If there were differences between these reviewers, cases were discussed by the full committee. Only definite events were included in this report. Reports of death were tracked through regular surveillance, and death certificates were obtained to supplement the hospital record review. Silent MI was assessed by ECGs obtained at baseline, 18 months, and 36 months and read using standard algorithms at a central reading center. 16 The time from randomization date to the first cardiovascular event, fatal or nonfatal, was used to define incidence during the trial. Total CVD events and a limited outcome of MI (excluding silent MI on ECG), stroke, or CVD death were examined. Analyses were conducted for the overall sample and by baseline history vs no history of cardiovascular disease.
Measurements
Participants were assessed at baseline and every 6 months at clinic visits by assessors who were also masked to intervention group assignment. The baseline assessments included selfreported demographic and contact information, medical and hospitalization history, medication inventory, ECG, physical examination, health care use, physical activity assessed with the Community Healthy Activities Model Program for Seniors questionnaire 17 and with accelerometry over 7-day periods (Actigraph Inc), cognitive testing, 400 m walk test, 18 the SPPB, body weight, blood pressure, and pulse rate. These measures were repeated during follow-up at varied intervals. 11 The SPPB consisted of a 4-m walk at usual pace, a timed repeated chair stand, and 3 increasingly difficult standing balance tests. 13, 19 Each measure was assigned a categorical score ranging from 0 (inability to complete the test) to 4 (best performance). A summary score ranging from 0 (worst performers) to 12 (best performers) was calculated by summing the 3 component scores. Home, telephone, and proxy assessments were attempted if the participants could not come to the clinic.
Statistical Considerations
The collection of cardiovascular events was added as a tertiary outcome after the sample size was fixed for the primary outcome. As such, the power for the combined cardiovascular events outcome was lower than desired. Assuming 8%/ year loss to follow-up, a 4%/year event rate in the SA group, and a 30% effect (HR of 0.7), we had only 51% power using a 2-sided test at the 5% level. With 80% power, we could detect a minimum effect size of 42% and with 90% power, a 47% effect. Baseline characteristics were summarized by intervention group using mean (SD) or percentages. The effect of the intervention on CVD (ie, time until the initial ascertainment) was tested based on a 2-tailed significance of .05 using the intention-to-treat approach, in which participants are grouped according to randomization assignment. To compare intervention arms, we used a likelihood ratio test from a Cox regression model, stratified by field center and sex. Interaction terms were entered into these Cox models to assess the consistency of the intervention effect across levels of prespecified baseline subgroups (ethnicity/race, sex, CVD, diabetes, walking speed, and SPPB score). No explicit assessment for multiplicity was made.
Results
The 1635 LIFE study participants were predominantly women (67%), with a mean (SD) age of 78.7 (5.2) years; 288 (20%) were African American, 108 (6%) were Hispanic or other race/ ethnic group, and 1239 (74%) were non-Latino white. The overall prevalence of CVD at baseline was 129 (8%) for MI, 104 (6.5%) for stroke, and 71 (4.2%) for heart failure with an overall baseline prevalence of 30%. Hypertension and diabetes were common (1151 [69%] and 415 [26%], respectively), while only 50 (3%) currently smoked cigarettes. Mean (SD) body mass index (calculated as weight in kilograms divided by height in meters squared) was 30 (5.5). Lipid levels, blood pressure, lowdensity lipoprotein cholesterol, and high-density lipoprotein cholesterol varied. Reflecting a high risk of disability, the mean SBBP was 7.4. These characteristics were balanced between the intervention groups ( Table 1) . Total incident CVD occurred in 14.3% overall, with 121 of 818 PA participants (14.8%) and 113 of 817 SA participants (13.8%) or 6.2 vs 5.6 events per 100 person-years (HR, 1.10; 95% CI, 0.85-1.42). For the more limited combined outcome of MI, stroke, or cardiovascular death, rates were 38 (4.6%) in the PA group and 37 (4.5%) in the SA group or 1.8 vs 1.7 events per 100 person-years (HR, 1.05; 95% CI, 0.67-1.66). There was no dif-ference in the rate of individual events between intervention groups (Table 2 and Figure 1) .
In prespecified subgroup analyses, there were no differences in rates of incident vs recurrent CVD (Figure 2 ). Among participants with an SPPB score less than 8, CVD rates were 14.2% in PA vs 17.7% in SA (HR, 0.76; 95% CI, 0.52-1.10), compared with 15.3% vs 10.5% (HR, 1.59; 95% CI, 1.09-2.30) among those with an SPPB score of 8 or 9 (P for interaction = .006). The interaction was not significantly different for the more limited composite end point of MI, stroke, or CVD death. For the limited outcome, among participants with an SPPB score less than 8, CVD rates were 5.4% in PA vs 5.6% in SA (HR, 0.94; 95% CI, 0.50-1.75), compared with 4.1% vs 3.6% (HR, 1.20; 95% CI, 0.62-2.34) among those with an SPPB score of 8 or 9 (P for interaction = .59) (eFigures 2 and 3 in the Supplement).
Because the observed effect of the intervention on CVD outcomes was marginally significant in lower vs higher SPPB subgroup, we examined the demographic, health characteristics, and types of CVD events by SPPB subgroup. We also examined the level of PA and level of exertion with PA during the trial by intervention group as well as SPPB subgroup (eTable in the Supplement). There were no differences in baseline characteristics by SPPB subgroup such as prevalent CVD, CVD risk factors, physical activity, or perceived level of exertion at baseline. There were more silent MIs by ECG in the higher SPPB subgroup but not more cardiovascular procedures, and this did not explain the relatively higher risk in the higher SPPB subgroup. Over the course of the study, higher SPPB subgroups had higher measured activity and lower perceived exertion than the lower SBBP subgroups in both the PA group and the SA group (eFigure 4 in the Supplement). Abbreviations: CHF, congestive heart failure; CVD, cardiovascular disease; HR, hazard ratio; py, person-years. a Incident event rates estimated from an exponential survival model.
b Hazard ratios from a proportional hazards model stratified by clinical site and sex. c Fatal or nonfatal myocardial infarction, stroke, cardiovascular death, silent myocardial infarction, angina/symptomatic coronary artery disease, peripheral artery disease, and abdominal aortic aneurysm (our predefined primary CVD end point). The total incidence is the number of participants who developed any of these conditions during the trial and thus will differ from the sum of the disease-specific totals. 
Discussion
Among participants in the LIFE Study, an aerobically based, moderately intensive PA program was not associated with reduced cardiovascular events. Participants in the LIFE study had a substantial baseline burden of prevalent CVD and cardiovascular risk factors and had a high rate of cardiovascular events (14.3%) during the 2.6 years of follow-up in the LIFE Study. In what is, to our knowledge, the only randomized trial of sustained PA in functionally limited older adults, the benefits of activity appear to be primarily reduced mobility disability 10 and perhaps improved cognition.
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The lack of benefit for CVS was similar in most subgroups including the one-third of the cohort with prevalent CVD at baseline. Individuals with poorer physical performance at baseline, defined as an SPPB score less than 8, had a more favorable benefit from PA for the outcome of CVD than those with a more moderate level of SPPB, as indicated by the statistically significant interaction term. In the LIFE study, a pattern of relatively more favorable benefit for older and more poorly functioning individuals was observed for the primary outcome of major mobility disability 10 and for other secondary outcomes. 10, 21, 22 In the case of the CVD outcome, the subgroup with less severe impairment had a higher rate of events in the PA group when compared with the SA/health education group. Further evaluation of the characteristics and activity of the SPPB 8 to 9 subgroup did not provide an obvious explanation for the higher event rate with PA in the high SPPB subgroup (8-9) vs the low SPPB subgroup (≤7). Participants with a higher baseline SPPB score reported a lower level of exertion with activity and had a similar relative increase in activity compared with the control group, as did the low SPPB subgroup. Of note, this interaction was not significant when CVD events were restricted to MI, stroke, and CVD death. While prespecified, these subgroup comparisons were meant to be hypothesisgenerating rather than designed to test specific hypotheses. There are several potential explanations for a lack of CVD reduction in the LIFE study. It is possible that the dose of activity was of suboptimal duration or intensity. Given the high burden of CVD, it is also possible that it was too late for this high-risk group to benefit. We also noted that both the SA and PA groups became more physically active by self-report, although only the PA group by actigraphy. 10 Potentially the contrast between the PA and SA groups was less than if a completely sedentary comparator had been used. It is also possible that the more frequent contact biased the PA group to report more events to the masked assessors or that PA could have precipitated some events in this vulnerable population. In the analysis stratified by SPPB score, when we excluded the symptomatic outcomes in the limited outcome, the difference by SPPB score was not statistically significant. There are several important limitations to this study. Follow-up was only 2.6 years on average. Statistical power was limited to detect small differences in rates or in subgroups.
Previous trials of activity in older adults have focused on intermediate outcomes such as lowering of blood pressure, weight, and improving function. 23, 24 In adults with type 2 diabetes, the Look AHEAD (Action for Health for Diabetes) study tested whether a lifestyle intervention that included sustained PA with weight loss could reduce CVD events. While findings were negative for the primary CVD outcome, 25 rates of disability were reduced. 24 Together, these studies suggest that physical activity should be recommended for improving quality of the remaining years of life.
Conclusions
Guidelines for PA for older adults include at least 150 minutes/ week of moderate-intensity aerobic activity with weight training. 23 The LIFE intervention meets these guidelines and proved to be safe and efficacious for the prevention of major mobility disability. The lack of association between increased PA and reduced CVD found here should not detract from efforts to promote a program of sustained walking and weight training in frail older adults.
